ArticleBMC cancer2026
Prognostic value of CA125, HE4, ROMA, and CPH-I in advanced epithelial ovarian cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOptimal cytoreductive surgery and platinum sensitivity are critical prognostic factors in advanced epithelial ovarian cancer (EOC). However, the preoperative value of routinely available serum biomarkers in predicting surgical outcomes, platinum resistance, and disease progression remains unclear.
methodsThis retrospective study included patients with benign ovarian tumors (n = 80), early-stage EOC (n = 84), and advanced EOC (n = 97) treated between January 2018 and June 2024. Serum cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) levels were measured before initial treatment, and the Risk of Ovarian Malignancy Algorithm (ROMA) and Copenhagen Index (CPH-I) values were calculated. Predictive performance for surgical outcomes, platinum resistance, and recurrence in advanced EOC was evaluated using receiver operating characteristic analysis, and progression-free survival was analyzed using Kaplan-Meier methods.
resultsSerum CA125, HE4, ROMA, and CPH-I levels progressively increased from the benign ovarian tumor group to the early-stage and advanced-stage EOC groups (P < 0.001). In advanced EOC, significantly higher biomarker levels were observed in patients with suboptimal cytoreduction and disease recurrence (P < 0.05). ROC analysis showed moderate discriminatory ability of all four biomarkers for suboptimal cytoreduction, platinum resistance, and recurrence (P < 0.05). ROMA and CPH-I showed relatively higher AUC values for predicting suboptimal cytoreduction, with AUCs of 0.807 and 0.800, respectively. Kaplan-Meier analysis showed that elevated CA125, HE4, ROMA, and CPH-I levels were significantly associated with shorter progression-free survival (P < 0.005). Multivariable Cox regression analyses further demonstrated that CA125, HE4, ROMA, and CPH-I remained independently associated with unfavorable progression-free survival after adjustment for clinicopathological confounders.
conclusionsElevated serum CA125, HE4, ROMA, and CPH-I are associated with unfavorable surgical outcomes, platinum resistance, and poor prognosis in advanced EOC. ROMA and CPH-I, in particular, may serve as valuable adjunctive tools for preoperative prediction of cytoreductive surgery outcomes, while all four biomarkers contribute to risk stratification for platinum sensitivity and disease progression. These findings support the potential role of combined serum biomarker assessment in guiding individualized treatment strategies for patients with advanced EOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.